Skip to main content
Fig. 9 | Journal of Nanobiotechnology

Fig. 9

From: A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune

Fig. 9

Elicitation of antitumor immune responses in vivo. (a) Immunofluorescence analysis for BRD4 in tumor tissue. (b) Immunofluorescence analysis for CRT expression in tumor tissue. (c, d) Infiltrating mature DCs and Treg cells in tumor tissue detected by immunofluorescence. Blue: DAPI; red: CD86 and Foxp3; green: CD11c. (e) Infiltrating CD4 and CD8 T cells in tumor tissue detected by immunofluorescence. Blue: DAPI; red: CD4; green: CD8. (f) The expression of TNF-α and IFN-γ in tumor tissue of different treatments. Blue: DAPI; red: TNF-α; green: IFN- γ. (g) Quantitative analysis of BRD4 CRT, CD11cCD86, Foxp3, CD8, TNF-α, IFN- γ. Data are presented as the mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us